To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
showing 1-10 of 43
AVAC and REACH for the Cure hosted a webinar to discuss how the environment may impact HIV cure strategies.
Join civil society organizations in PEPFAR recipient countries to discuss the status and political context of the current reauthorization and mobilize to call on the US Congress to recommit this life sustaining program. Bring your questions and please share this invitation widely in your relevant networks.
The Pandemic Accord negotiations are ongoing, and should come to fruition next year. What do they mean for your work, your country, and the future of global health? On Tuesday, November 21, 8:00 to 9:30 AM EST / 2:00 to 3:30 PM CEST, advocates came...
Tuesday, November 28 Between the recent accelerated growth in global PrEP initiations, and the introduction of new PrEP products like cabotegravir and the dapivirine vaginal ring, the field of PrEP data has never been more exciting or more...
This webinar explored what makes curing HIV so challenging, the strategies being pursued, and what is happening in locally in NYC!
HPTN 096: Building Equity Through Advocacy – An Integrated, Status-Neutral Approach for Ending the Epidemic Among Black Gay Men in the South
The Choice Agenda and partners hosted a fascinating discussion about a novel, much-needed HIV prevention research study – HPTN 096 on November 15. Currently in the field, the study addresses social, structural, institutional, and behavioral barriers to HIV prevention and care. Visit the study website here.
Hear results from STI landscaping projects conducted in seven different countries from East and Southern Africa that explored needs for STI vaccines and diagnostics.
Syphilis rates have increased drastically in recent years. Learn how others are addressing these rising rates and the techniques clinicians are using to detect, treat, and prevent infections. Co-hosted with NACCHO and NNPTC. Webinar Recording /...
On October 5, The Choice Agenda (TCA) and the National Coalition of STD Directors (NCSD) hosted a discussion on the roll out of Doxycycline as STI PEP for helping gay, bisexual, and other men who have sex with men and transgender women reduce bacterial STIs, including gonorrhea, chlamydia, and syphilis.
On Wednesday, September 6, The Choice Agenda (TCA), the International Network of People Who Use Drugs (INPUD) and our wonderful expert speakers discussed the health and wellness priorities of people who use/inject drugs, and how these communities (“key populations”) intersect across PrEP research, development, and implementation activities.
showing 1-10 of 43